Background Patients with radioiodine-refractory differentiated thyroid cancer (DTC)
previously treated with vascular endothelial growth factor receptor (VEGFR)-targeted …

Purpose Sorafenib and lenvatinib are oral multikinase inhibitors targeting vascular
endothelial growth factor receptor (VEGFR) and approved for radioiodine (RAI)-refractory …

Background: Cabozantinib targets tyrosine kinases including MET, vascular endothelial
growth factor (VEGF) receptor 2, and rearranged during transfection (RET). Differentiated …

Background Treatment with radioactive iodine is effective for many patients with progressive,
locally advanced or metastatic, differentiated thyroid cancer. However, some patients …

Background About half of patients with papillary thyroid cancer have tumours with activating
BRAF V600E mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for …

Purpose In the Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid
(SELECT), lenvatinib significantly prolonged progression-free survival (PFS) versus placebo …

BACKGROUND Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor of the vascular
endothelial growth factor receptors 1 through 3 (VEGFR1‐VEGFR3), fibroblast growth factor …

Background: In the Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid
(SELECT) phase 3 trial on advanced radioactive iodine–refractory differentiated thyroid …

Background Primary analysis of the double-blind, phase III Efficacy of XL184 (Cabozantinib)
in Advanced Medullary Thyroid Cancer (EXAM) trial demonstrated significant improvement …

Background Patients with radioactive iodine (131 I)-refractory locally advanced or metastatic
differentiated thyroid cancer have a poor prognosis because of the absence of effective …